Report Overview

The global leukemia therapeutics market was pegged at US$ 13.95 billion in 2021 and is expected to witness a CAGR of 6.5% during the forecast period.

Market Fundamentals

Leukemia is a cancer of the blood cells, and it generally refers to cancer of the WBCs. In leukemia, the bone marrow produces an excessive amount of white blood cells that function abnormally. Leukemia initiates in the blood-forming tissues such as the bone marrow and lymphatic system, the bone marrow is the part where red blood cells, white blood cells, and platelets are produced. Mutation of genes and genetic disorders are the leading causes of leukemia. There are various types of leukemia such as acute myeloid leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, and chronic lymphocytic leukemia. Leukemia commonly occurs in adults older than 55, but nowadays it is one of the most common cancers in children below 15 years of age. Leukemia is more common in men than in women. Treatments for leukemia include radiation, chemotherapy, and stem cell transplantation.

[5664234234]

Market Dynamics                      

The rising geriatric population, high prevalence of leukemia, and increase in research & development activities for novel immunotherapies are some of the major factors expected to fuel the market growth. Moreover, an increasing number of approvals by regulatory bodies and increasing cancer research funding are some of the other factors playing a pivotal role in propelling the global leukemia therapeutics market. However, the high cost of treatment and side effects related to the treatment are hindering the growth of the leukemia therapeutics market to a certain extent.

Market Ecosystem

The global leukemia therapeutics market has been analyzed from four perspectives: type, treatment type, mode of administration, and region. 

Leukemia Therapeutics Market by Type

[65765543]

Based on type, the leukemia therapeutics market has been segmented into acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL). Chronic lymphocytic leukemia held the largest share of the market in 2021. The large share of the market can be attributed to the growing incidence of chronic lymphocytic leukemia coupled with the rising geriatric population and rising incidence in children. Increasing investments and funding for the development of innovative & novel cancer drugs like CAR T-cell and combination drugs are also playing a pivotal role in driving segmental growth. 

Leukemia Therapeutics Market by Treatment Type

Based on treatment type, the market has been segmented into targeted drugs, chemotherapy, and immunotherapy. The targeted drugs segment accounted for the largest share of the market in 2021, owing to the wide usage of these drugs for the treatment of leukemia. Moreover, higher efficacy and fewer side effects are some of the advantages of the targeted drugs which make them preferable. For instance, patients suffering from chronic myelogenous leukemia have a specific chromosome called the Philadelphia chromosome which produces an abnormal protein that enhances the growth of leukemia. The abnormal protein can be blocked with the use of targeted therapy. Furthermore, the increasing number of FDA-approved drugs and the rising expenditure on the development of novel drugs are also expected to propel the growth of the targeted drugs for leukemia during the forecasted period. FDA has approved 6 different CAR T- cell therapy for the treatment of leukemia since 2017.

Leukemia Therapeutics Market by Mode of Administration

Based on the mode of administration, the market has been segmented into injectable and oral. The injectable route accounted for the largest share of the leukemia therapeutics market in 2021. The majority of leukemia drugs available on the market are injectable drugs. There has been rising adoption of injectable drugs in targeted therapy or chemotherapy owing to their effectiveness as compared to other dosage forms. These factors are expected to boost the growth of the segment in the market

Leukemia Therapeutics Market by Region

Based on region, the global leukemia therapeutics market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America dominated the market for leukemia therapeutics holding the largest market share in 2021 followed by Europe. Several factors have contributed to the growth of the leukemia therapeutics market in the North America region including the rising geriatric population and increasing prevalence of leukemia. According to the National Cancer Institute, it is estimated that in 2022 there will be 60,650 new cases of Leukemia in the U.S. of which estimated death will be 24,000. Leukemia contributes to about 3.2% of all cancer cases in the U.S. Moreover, the launch of new drugs & therapies, the increasing number of FDA approvals for drugs, and the rising investments in the R&D of cancer drugs are other important factors boosting the market growth in the North America region.

Competitive Landscape

Some of the prominent players operating in the global leukemia therapeutics market include

• Novartis International AG 
• Bristol-Myers Squibb
• F. Hoffmann-La Roche Ltd
• Sanofi S.A
• AbbVie Inc.
• Gilead Sciences, Inc.
• Takeda Pharmaceutical Company Limited
• GlaxoSmithKline plc
• Amgen Inc.
• Pfizer Inc.

Strategic Developments

• In July 2022, Ascentage Pharma received approval from Health Canada for phase 1b clinical trials for its novel drug candidate, olverembatinib (HQP1351) for the treatment of refractory chronic myeloid leukemia
• In June 2022, Novartis received a positive opinion from CHMP of the European Medical agency for the marketing authorization for Scemblix, a novel treatment for adult patients with chronic myeloid leukemia
• In June 2022, Race Oncology an Australia-based Biotech company advanced its studies of Zantrene a cancer-treating drug. The drug was reported to protect the heart against the damage in chemotherapy and the good result were observed in the phase 2 study in acute myeloid leukemia
• In Aug 2021, Pfizer Inc. acquired Trillium Therapeutics Inc., a clinical-stage immune-oncology company developing innovative therapies for cancer. This acquisition was aimed to strengthen Pfizer’s with this Pfizer wants to strengthen its position in oncology leadership in Oncology with the addition of next-generation, investigational immuno-therapeutics for hematological malignancies

Frequently Asked Questions About This Report